Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33155
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWagner, Theresa Maria-
dc.contributor.authorJanice, Jessin-
dc.contributor.authorSchulz, Mark-
dc.contributor.authorBallard, Susan A-
dc.contributor.authorda Silva, Anders Goncalves-
dc.contributor.authorCoombs, Geoffrey W-
dc.contributor.authorDaley, Denise A-
dc.contributor.authorPang, Stanley-
dc.contributor.authorMowlaboccus, Shakeel-
dc.contributor.authorStinear, Tim-
dc.contributor.authorHegstad, Kristin-
dc.contributor.authorHowden, Benjamin P-
dc.contributor.authorSundsfjord, Arnfinn-
dc.date2023-
dc.date.accessioned2023-06-22T06:48:55Z-
dc.date.available2023-06-22T06:48:55Z-
dc.date.issued2023-07-
dc.identifier.citationInternational Journal of Antimicrobial Agents 2023-07; 62(1)en_US
dc.identifier.issn1872-7913-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33155-
dc.description.abstractVancomycin variable enterococci (VVE) are van-positive enterococci with a vancomycin-susceptible phenotype (VVE-S) that can convert to a resistant phenotype (VVE-R) and be selected for during vancomycin exposure. VVE-R outbreaks have been reported in Canada and Scandinavian countries. The aim of this study was to examine the presence of VVE in whole genome sequenced (WGS) Australian bacteremia Enterococcus faecium (Efm) isolates collected through the Australian Group on Antimicrobial resistance (AGAR) network. Eight potential VVEAus isolates, all identified as Efm ST1421, were selected based on the presence of vanA and a vancomycin-susceptible phenotype. During vancomycin selection, two potential VVE-S harboring intact vanHAX genes, but lacking the prototypic vanRS and vanZ genes, reverted to a resistant phenotype (VVEAus-R). Spontaneous VVEAus-R reversion occurred at a frequency of 4-6 × 10-8 resistant colonies per parent cell in vitro after 48 h and led to high-level vancomycin and teicoplanin resistance. The S to R reversion was associated with a 44-bp deletion in the vanHAX promoter region and an increased vanA plasmid copy number. The deletion in the vanHAX promoter region enables an alternative constitutive promoter for the expression of vanHAX. Acquisition of vancomycin resistance was associated with a low fitness cost compared with the corresponding VVEAus-S isolate. The relative proportion of VVEAus-R vs. VVEAus-S decreased over time in serial passages without vancomycin selection. Efm ST1421 is one of the predominant VanA-Efm multilocus sequence types found across most regions of Australia, and has also been associated with a major prolonged VVE outbreak in Danish hospitals.en_US
dc.language.isoeng-
dc.subjectEnterococcus faeciumen_US
dc.subjectTeicoplaninen_US
dc.subjectVREen_US
dc.subjectVancomycinen_US
dc.subjectVancomycin variableen_US
dc.titleReversible vancomycin susceptibility within emerging ST1421 Enterococcus faecium strains is associated with rearranged vanA-gene clusters and increased vanA plasmid copy number.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternational Journal of Antimicrobial Agentsen_US
dc.identifier.affiliationResearch group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.en_US
dc.identifier.affiliationNorwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.en_US
dc.identifier.affiliationThe Peter Doherty Instituteen_US
dc.identifier.affiliationThe Microbiological Diagnostic Unit Public Health Laboratory and Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, University of Melbourne.en_US
dc.identifier.affiliationAntimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.en_US
dc.identifier.affiliationAustralian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.en_US
dc.identifier.affiliationAntimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.en_US
dc.identifier.affiliationThe Microbiological Diagnostic Unit Public Health Laboratory and Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, University of Melbourne, Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.en_US
dc.identifier.affiliationResearch group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.en_US
dc.identifier.affiliationThe Microbiological Diagnostic Unit Public Health Laboratory and Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, University of Melbourne, Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.en_US
dc.identifier.affiliationResearch group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway; The Microbiological Diagnostic Unit Public Health Laboratory and Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, University of Melbourne, Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.en_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.doi10.1016/j.ijantimicag.2023.106849en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37187337-
dc.description.volume62-
dc.description.issue1-
dc.description.startpage106849-
dc.subject.meshtermssecondaryVancomycin/pharmacology-
dc.subject.meshtermssecondaryEnterococcus faecium/genetics-
dc.subject.meshtermssecondaryAnti-Bacterial Agents/pharmacology-
dc.subject.meshtermssecondaryAustralia/epidemiology-
dc.subject.meshtermssecondaryEnterococcus/genetics-
dc.subject.meshtermssecondaryPlasmids/genetics-
dc.subject.meshtermssecondaryGram-Positive Bacterial Infections/epidemiology-
dc.subject.meshtermssecondaryBacterial Proteins/genetics-
local.name.researcherHowden, Benjamin P
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Nov 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.